windeln.de SE

  • WKN: WNDL19
  • ISIN: DE000WNDL193
  • Land: Deutschland

Nachricht vom 07.02.2019 | 19:36

windeln.de SE: windeln.de SE resolves on capital increase with subscription rights to finance growth in China and restructuring until completion

windeln.de SE / Key word(s): Capital Increase
windeln.de SE: windeln.de SE resolves on capital increase with subscription rights to finance growth in China and restructuring until completion

07-Feb-2019 / 19:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


windeln.de SE resolves on capital increase with subscription rights to finance growth in China and restructuring until completion

The Management Board of windeln.de SE ("windeln.de" or the "Company") today resolved, with the approval of the Supervisory Board, to increase the share capital based on the resolution of the Extraordinary General Meeting on January 9, 2019 from currently EUR 3,113,647, divided into 3,113,647 no-par value bearer shares, by up to 6,850,023 shares to up to EUR 9,963,670 by issuing up to 6,850,023 New Shares, each representing a pro rata amount in the share capital of EUR 1.00 per share ("New Shares"). The New Shares are entitled to dividends from January 1, 2018. The New Shares will not be admitted to trading at the stock exchange immediately, but presumably in the second quarter of 2019.

Up to 3,369,298 New Shares will be offered as part of a rights offering to the Company's shareholders by way of indirect subscription rights at a subscription ratio of 1:2.2, i.e. 1 existing share entitles to subscribe for 2.2 New Shares from the capital increase (the "Rights Offering"). The subscription price was fixed at EUR 1.48 per New Share resulting in gross proceeds from the Rights Offering of up to EUR 4.99 million. The subscription rights for fractional amounts were excluded. An organized trading of subscription rights will not take place. The subscription offer is expected to be published in the Federal Gazette on February 12, 2019. The subscription period will begin on February 14, 2019 (0:00 CET) and end on February 28, 2019 (24:00 CET). The record date for the allocation of subscription rights is expected to be February 13, 2019.

Remaining New Shares not subscribed by shareholders in the connection of the Rights Offering as well as up to 3,480,725 New Shares in respect to which existing shareholders agreed not to exercise their subscription rights will be offered to interested investors in a private placement at a price of EUR 1.48 per share.

The Company has received commitment letters for the Private Placement covering a maximum volume of EUR 7.25 million at the subscription price from several investors, including from two new Asian investors, under which the investors' obligations are in part subject to the fulfillment of minimum allocation quotas.

The Fintech Group Bank AG with its representative office BankM is accompanying the capital increase and will offer the new shares to the shareholders in accordance with the subscription offer.

The Company expects gross issue proceeds of a high one digit million Euro amount. With the gross issue proceeds, windeln.de intends to realize projects for the announced growth course in China and to conclude the restructuring program.

Further information can be found in the subscription offer. The documents will be available in the Federal Gazette and the website of windeln.de (corporate.windeln.de).




Contact:
Corporate Communications
Sophia Kursawe
Phone: +49 (89) 41 61 71 52 65
Email: presse@windeln.de

07-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

UniDevice AG: Rekord-Ergebnis in 2018

Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.

News im Fokus

Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2018

21. Februar 2019, 11:51

Aktueller Webcast

Ströer SE & Co. KGaA

Vorläufige Geschäftszahlen 2018

26. Februar 2019

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

21. Februar 2019